Angiex Inc., a privately held biotech startup based in Cambridge, Mass., has secured $31,000,000 in funding from investors. The company’s mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. This significant investment marks a pivotal moment for Angiex as it continues to advance its innovative drug development efforts.
Founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology, Angiex is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs). These advanced therapies are designed to release therapeutic payloads directly into the nucleus or cytosol, precisely where the site of payload action is located. The successful closure of this funding round underscores investor confidence in Angiex’s proprietary technology and its potential to offer novel therapeutic approaches in oncology.
The newly raised capital will be strategically deployed to accelerate the development of Angiex’s ND-ADC pipeline. This includes advancing its lead drug candidates through critical preclinical stages and initiating early-stage clinical trials. The funds will also support continued research into its unique biological transport mechanisms, further expanding the understanding and application of its drug delivery platform. Additionally, Angiex plans to invest in scaling its scientific and operational teams to support its ambitious growth trajectory.
This funding round positions Angiex Inc. to significantly progress its mission of transforming cancer therapy. The company is poised to leverage this capital to bring its innovative drug candidates closer to patients, expanding its impact on the oncology landscape and pursuing further advancements in its unique drug delivery technology with the goal of addressing unmet needs in cancer treatment.
